España
El Martes noche supongo que el CEO, Stan, se creia que iba a entrar en el programa de Cramer con el precio subiendo como la espuma ... tuvo que ser duro aquel dia con esta puñalada trapera que le metio el analista de Piper Jaffray con el que lleva tratando tantos años ...
Por cierto, que llevamos ya hoy 10 millones de cromos joer
NVAX
Vendeis muy pronto, pero la liquidez tambien es importante, si vienen de pluses mejor.
XOMA
Templarivm, que hoy te he comprado yo tus cromos. :)
Espero que te recuperes con XOMA, suerte.
Que somos muchos tirando le al Ebola y con apoyo gubernamental
--
In the third and fourth government grants toward Ebola vaccines in two weeks, NewLink Genetics ($NLNK) won a total of $26.1 million in funding from the DOD's Defense Threat Reduction Agency and HHS' BARDA in the span of just over a week.
GlaxoSmithKline is working on its candidate as a single jab as well as with a booster from Emergent BioSolutions ($EBS). Johnson & Johnson ($JNJ) struck a $28.5 million partnership with BARDA this month to further develop the prime-boost regimen on which it is collaborating with Bavarian Nordic. And just last week, a team led by Inovio Pharma ($INO) scored $24 million from DARPA to develop Ebola treatments and vaccines.
http://www.fiercevaccines.com/story/newlink-wins-81m-dod-advance-ebola-vaccine/2015-09-28?utm_medium=nl&utm_source=internal
NVAX
Todas para tí, jajaja... Curiosa cotización en estos momentos: 6,66...!!!
"Le haré una oferta que no rechazará" - Vito Corleone (Marlon Brando) El Padrino
ocat
Zach vuelve a la carga esperemos le de otro arreón
http://seekingalpha.com/article/3546406-addressing-a-major-public-need-the-ocata-preclinical-pipeline-part-2-platelet-production?auth_param=6jmkp:1b0r5uc:5ef30a86f2fe731a721797e89e6ae01f
estudio preclinico para la optención de plaquetas, rumor de partner y al final hace falta pasta...
tambien hay reparto de cromos 6 sec form4
Novavax Announces Management Promotion
GAITHERSBURG, Md., Oct. 01, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Jody Lichaa has been named Vice President, Quality Assurance. Ms. Lichaa joined Novavax as the Executive Director, Quality Assurance in October 2011. She is responsible for providing strategy, oversight, and direction of the Company’s quality assurance.
Prior to joining Novavax, she was Senior Director, Quality at PharmAthene from 2005 until 2011, where she managed that company’s global QA/QC activities. Her prior experience includes quality assurance positions of increasing responsibility in a number of companies including Baxter, Shire and BioReliance. Ms. Lichaa received her B.S. in Toxicology from Northeastern University.
“Jody has successfully developed and managed a talented quality assurance team that has been instrumental in the ongoing development of our vaccine candidates,” said Stanley C. Erck, President and CEO. “Jody’s talent and expertise will continue to be critical as we prepare for Phase 3 development of our RSV F Vaccines.”
Creo que los indices tiraran al verde mañana asi que por eso he acumulado 5k mas a 6,6.
Asi que en cuanto el precio vuelva a situarse sobre los 7$, espero que mañana mismo, le meto un stop unos centavos por delante del precio de compra por si a los mercados les da por irse a los infiernos que muchos profetizan ... y santaspascuas.
20k cromos posicion completada, no compro mas.
NVAX
